| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Injuries | 40 | 2023 | 764 | 7.070 |
Why?
|
| Cognition Disorders | 28 | 2016 | 550 | 3.420 |
Why?
|
| Brain Injuries, Traumatic | 13 | 2024 | 361 | 3.050 |
Why?
|
| Neuropsychological Tests | 32 | 2024 | 919 | 2.190 |
Why?
|
| Memory Disorders | 8 | 2024 | 234 | 2.130 |
Why?
|
| Neuropsychiatry | 6 | 2020 | 12 | 2.020 |
Why?
|
| Bipolar Disorder | 11 | 2023 | 344 | 1.900 |
Why?
|
| Cholinesterase Inhibitors | 5 | 2024 | 100 | 1.690 |
Why?
|
| Mental Disorders | 18 | 2014 | 828 | 1.500 |
Why?
|
| Neurosciences | 3 | 2017 | 50 | 1.460 |
Why?
|
| Indans | 2 | 2024 | 55 | 1.300 |
Why?
|
| Piperidines | 2 | 2024 | 208 | 1.190 |
Why?
|
| Crying | 6 | 2014 | 12 | 1.100 |
Why?
|
| Depressive Disorder, Major | 6 | 2023 | 399 | 1.100 |
Why?
|
| Mood Disorders | 6 | 2023 | 124 | 1.050 |
Why?
|
| Brain | 21 | 2023 | 2999 | 1.040 |
Why?
|
| Consciousness Disorders | 5 | 2023 | 23 | 1.030 |
Why?
|
| Affective Symptoms | 5 | 2014 | 59 | 0.990 |
Why?
|
| Psychotic Disorders | 5 | 2015 | 138 | 0.940 |
Why?
|
| Frontotemporal Dementia | 2 | 2023 | 43 | 0.940 |
Why?
|
| Nootropic Agents | 1 | 2024 | 27 | 0.930 |
Why?
|
| Laughter | 5 | 2014 | 10 | 0.910 |
Why?
|
| Aggression | 4 | 2014 | 222 | 0.900 |
Why?
|
| Alcoholism | 6 | 2022 | 231 | 0.860 |
Why?
|
| Consciousness | 1 | 2023 | 49 | 0.840 |
Why?
|
| Hypoxia-Ischemia, Brain | 3 | 2010 | 81 | 0.830 |
Why?
|
| Humans | 125 | 2024 | 125189 | 0.820 |
Why?
|
| Receptors, Cholinergic | 4 | 2011 | 84 | 0.800 |
Why?
|
| Evoked Potentials, Auditory | 6 | 2004 | 53 | 0.790 |
Why?
|
| Nervous System Diseases | 7 | 2020 | 375 | 0.770 |
Why?
|
| Lupus Erythematosus, Systemic | 8 | 2013 | 193 | 0.760 |
Why?
|
| Memory | 7 | 2024 | 359 | 0.740 |
Why?
|
| Forensic Psychiatry | 2 | 2013 | 13 | 0.720 |
Why?
|
| Psychomotor Performance | 5 | 2011 | 182 | 0.710 |
Why?
|
| Psychiatry | 4 | 2016 | 263 | 0.690 |
Why?
|
| Irritable Mood | 3 | 2022 | 9 | 0.680 |
Why?
|
| Functional Laterality | 8 | 2016 | 184 | 0.670 |
Why?
|
| Brain Concussion | 5 | 2023 | 228 | 0.670 |
Why?
|
| Cognition | 7 | 2018 | 728 | 0.670 |
Why?
|
| Adult | 50 | 2024 | 29628 | 0.660 |
Why?
|
| Acetylcholine | 4 | 2011 | 83 | 0.630 |
Why?
|
| Hippocampus | 9 | 2019 | 824 | 0.620 |
Why?
|
| Hallucinations | 2 | 2016 | 26 | 0.620 |
Why?
|
| Amnesia | 3 | 2023 | 20 | 0.620 |
Why?
|
| Brain Injury, Chronic | 2 | 2013 | 21 | 0.600 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 392 | 0.590 |
Why?
|
| Attention | 9 | 2019 | 201 | 0.590 |
Why?
|
| Confusion | 2 | 2020 | 16 | 0.590 |
Why?
|
| Antipsychotic Agents | 4 | 2015 | 371 | 0.580 |
Why?
|
| Diagnosis, Differential | 16 | 2017 | 1897 | 0.570 |
Why?
|
| Cholinergic Fibers | 3 | 2011 | 9 | 0.570 |
Why?
|
| Aphasia | 2 | 2015 | 13 | 0.560 |
Why?
|
| Neurology | 2 | 2010 | 107 | 0.530 |
Why?
|
| Politics | 1 | 2017 | 59 | 0.520 |
Why?
|
| Male | 64 | 2024 | 61525 | 0.520 |
Why?
|
| Severity of Illness Index | 12 | 2011 | 2913 | 0.510 |
Why?
|
| Capgras Syndrome | 1 | 2016 | 3 | 0.510 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2024 | 234 | 0.510 |
Why?
|
| Impulsive Behavior | 2 | 2014 | 145 | 0.510 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2014 | 211 | 0.510 |
Why?
|
| Expert Testimony | 2 | 2013 | 37 | 0.490 |
Why?
|
| Middle Aged | 39 | 2024 | 26927 | 0.490 |
Why?
|
| Dopamine Agents | 2 | 2006 | 28 | 0.490 |
Why?
|
| Recovery of Function | 5 | 2019 | 445 | 0.490 |
Why?
|
| Pseudobulbar Palsy | 2 | 2005 | 4 | 0.480 |
Why?
|
| Dementia | 3 | 2013 | 452 | 0.480 |
Why?
|
| Stroke Rehabilitation | 2 | 2005 | 59 | 0.470 |
Why?
|
| Journalism, Medical | 1 | 2015 | 9 | 0.470 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2015 | 44 | 0.460 |
Why?
|
| Double-Blind Method | 6 | 2024 | 1637 | 0.450 |
Why?
|
| West Nile Fever | 2 | 2008 | 139 | 0.450 |
Why?
|
| Connectome | 3 | 2023 | 99 | 0.440 |
Why?
|
| Football | 1 | 2013 | 31 | 0.420 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 197 | 0.410 |
Why?
|
| Mental Status Schedule | 2 | 2010 | 44 | 0.410 |
Why?
|
| Schizophrenia | 4 | 2015 | 311 | 0.410 |
Why?
|
| Psychotropic Drugs | 1 | 2014 | 122 | 0.410 |
Why?
|
| Magnetic Resonance Imaging | 19 | 2023 | 3573 | 0.400 |
Why?
|
| Behavioral Symptoms | 1 | 2013 | 25 | 0.400 |
Why?
|
| Surveys and Questionnaires | 5 | 2023 | 3729 | 0.400 |
Why?
|
| Neurotransmitter Agents | 3 | 2008 | 147 | 0.400 |
Why?
|
| Violence | 1 | 2013 | 115 | 0.380 |
Why?
|
| Post-Concussion Syndrome | 3 | 2013 | 52 | 0.380 |
Why?
|
| Phenylcarbamates | 2 | 2009 | 15 | 0.380 |
Why?
|
| Psychiatric Status Rating Scales | 10 | 2015 | 816 | 0.370 |
Why?
|
| Female | 48 | 2024 | 66806 | 0.360 |
Why?
|
| Veterans | 4 | 2023 | 1748 | 0.360 |
Why?
|
| Electroencephalography | 4 | 2015 | 865 | 0.350 |
Why?
|
| Indians, North American | 2 | 2010 | 58 | 0.350 |
Why?
|
| Treatment Outcome | 14 | 2024 | 12392 | 0.350 |
Why?
|
| Military Personnel | 2 | 2023 | 210 | 0.350 |
Why?
|
| Suicide | 1 | 2013 | 176 | 0.340 |
Why?
|
| Delirium | 2 | 2024 | 55 | 0.340 |
Why?
|
| Capital Punishment | 1 | 2010 | 3 | 0.340 |
Why?
|
| Neuroprotective Agents | 2 | 2009 | 163 | 0.330 |
Why?
|
| Cerebral Cortex | 5 | 2019 | 452 | 0.330 |
Why?
|
| Public Policy | 1 | 2010 | 51 | 0.320 |
Why?
|
| Injury Severity Score | 5 | 2019 | 226 | 0.310 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2015 | 110 | 0.310 |
Why?
|
| Cognitive Dysfunction | 2 | 2024 | 236 | 0.310 |
Why?
|
| Amygdala | 3 | 2018 | 76 | 0.310 |
Why?
|
| Reflex | 1 | 2009 | 51 | 0.310 |
Why?
|
| Geriatric Assessment | 1 | 2010 | 174 | 0.310 |
Why?
|
| Affect | 4 | 2008 | 158 | 0.300 |
Why?
|
| Central Nervous System Stimulants | 4 | 2016 | 127 | 0.300 |
Why?
|
| Physical Therapy Modalities | 2 | 2005 | 52 | 0.290 |
Why?
|
| Insanity Defense | 1 | 2008 | 3 | 0.290 |
Why?
|
| Neuroanatomy | 2 | 2023 | 11 | 0.290 |
Why?
|
| White Matter | 2 | 2024 | 181 | 0.290 |
Why?
|
| Crime | 1 | 2008 | 26 | 0.290 |
Why?
|
| Depression | 4 | 2009 | 1237 | 0.290 |
Why?
|
| Dibenzothiazepines | 1 | 2007 | 14 | 0.290 |
Why?
|
| Stroke | 5 | 2015 | 989 | 0.290 |
Why?
|
| Rivastigmine | 3 | 2021 | 17 | 0.280 |
Why?
|
| Aged | 16 | 2024 | 19870 | 0.280 |
Why?
|
| Physician-Patient Relations | 1 | 2010 | 429 | 0.270 |
Why?
|
| Hiccup | 1 | 2006 | 6 | 0.260 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 1099 | 0.260 |
Why?
|
| Alzheimer Disease | 3 | 2011 | 798 | 0.250 |
Why?
|
| Adrenergic Agents | 1 | 2006 | 12 | 0.250 |
Why?
|
| Behavioral Sciences | 1 | 2006 | 8 | 0.250 |
Why?
|
| Methylphenidate | 3 | 2016 | 58 | 0.250 |
Why?
|
| Neuropsychology | 1 | 2006 | 23 | 0.250 |
Why?
|
| Hemiplegia | 1 | 2005 | 45 | 0.240 |
Why?
|
| Paresis | 1 | 2005 | 35 | 0.240 |
Why?
|
| Motor Skills | 1 | 2005 | 83 | 0.240 |
Why?
|
| Specialization | 1 | 2006 | 75 | 0.240 |
Why?
|
| Disability Evaluation | 3 | 2019 | 191 | 0.240 |
Why?
|
| Amantadine | 1 | 2004 | 10 | 0.240 |
Why?
|
| Upper Extremity | 1 | 2005 | 54 | 0.240 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2021 | 627 | 0.230 |
Why?
|
| Research Design | 1 | 2009 | 695 | 0.230 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2004 | 9 | 0.230 |
Why?
|
| Neurologic Examination | 5 | 2008 | 193 | 0.230 |
Why?
|
| Psychosurgery | 1 | 2004 | 27 | 0.230 |
Why?
|
| Healthy Aging | 1 | 2024 | 9 | 0.230 |
Why?
|
| Mental Competency | 1 | 2024 | 51 | 0.220 |
Why?
|
| Emotions | 3 | 2019 | 356 | 0.220 |
Why?
|
| Exercise Therapy | 1 | 2005 | 154 | 0.220 |
Why?
|
| Comorbidity | 3 | 2014 | 1534 | 0.210 |
Why?
|
| Neuroimaging | 5 | 2019 | 336 | 0.210 |
Why?
|
| Hospital Mortality | 1 | 2008 | 1025 | 0.210 |
Why?
|
| Myelin Sheath | 1 | 2024 | 122 | 0.210 |
Why?
|
| Analysis of Variance | 5 | 2007 | 1020 | 0.210 |
Why?
|
| Critical Care | 1 | 2008 | 657 | 0.200 |
Why?
|
| Substance-Related Disorders | 2 | 2020 | 460 | 0.200 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 2174 | 0.200 |
Why?
|
| Magnetoencephalography | 5 | 2011 | 33 | 0.200 |
Why?
|
| Valproic Acid | 2 | 2022 | 165 | 0.190 |
Why?
|
| Delusions | 2 | 2015 | 17 | 0.190 |
Why?
|
| Young Adult | 7 | 2024 | 9053 | 0.190 |
Why?
|
| Regression Analysis | 5 | 2013 | 781 | 0.190 |
Why?
|
| Thalamus | 2 | 2018 | 83 | 0.190 |
Why?
|
| Prisoners | 1 | 2021 | 35 | 0.190 |
Why?
|
| Dominance, Cerebral | 1 | 2000 | 56 | 0.180 |
Why?
|
| Central Nervous System Agents | 1 | 2000 | 14 | 0.180 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2020 | 17 | 0.170 |
Why?
|
| Rehabilitation Centers | 1 | 2020 | 34 | 0.170 |
Why?
|
| Suicidal Ideation | 2 | 2023 | 220 | 0.170 |
Why?
|
| Hospitalization | 1 | 2008 | 1783 | 0.170 |
Why?
|
| Conversion Disorder | 1 | 2020 | 9 | 0.170 |
Why?
|
| Physical and Rehabilitation Medicine | 1 | 2020 | 34 | 0.160 |
Why?
|
| Electroconvulsive Therapy | 2 | 2014 | 68 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2017 | 6153 | 0.160 |
Why?
|
| Chronic Traumatic Encephalopathy | 1 | 2019 | 6 | 0.160 |
Why?
|
| Acceptance and Commitment Therapy | 1 | 2020 | 40 | 0.160 |
Why?
|
| Glasgow Coma Scale | 2 | 2011 | 205 | 0.160 |
Why?
|
| Magnetic Resonance Spectroscopy | 5 | 2013 | 294 | 0.160 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2019 | 15 | 0.160 |
Why?
|
| Facial Expression | 1 | 2019 | 27 | 0.160 |
Why?
|
| Sensory Thresholds | 1 | 1999 | 35 | 0.160 |
Why?
|
| Biomechanical Phenomena | 2 | 2011 | 245 | 0.160 |
Why?
|
| Lithium Compounds | 1 | 2018 | 13 | 0.150 |
Why?
|
| Habenula | 1 | 2018 | 41 | 0.150 |
Why?
|
| Brain Diseases | 1 | 2000 | 300 | 0.140 |
Why?
|
| Spatial Memory | 1 | 2017 | 37 | 0.140 |
Why?
|
| Glutamic Acid | 2 | 2011 | 203 | 0.140 |
Why?
|
| Sertraline | 2 | 2009 | 44 | 0.140 |
Why?
|
| Choline | 4 | 2013 | 54 | 0.140 |
Why?
|
| Suicide, Attempted | 1 | 2018 | 130 | 0.140 |
Why?
|
| Aged, 80 and over | 4 | 2011 | 6598 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 2891 | 0.140 |
Why?
|
| Factor Analysis, Statistical | 1 | 2017 | 235 | 0.130 |
Why?
|
| Encephalitis | 1 | 2017 | 111 | 0.130 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2016 | 21 | 0.130 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 634 | 0.120 |
Why?
|
| Aspartic Acid | 3 | 2011 | 73 | 0.120 |
Why?
|
| Prognosis | 4 | 2019 | 4645 | 0.120 |
Why?
|
| Range of Motion, Articular | 2 | 2005 | 74 | 0.120 |
Why?
|
| Frontal Lobe | 3 | 2013 | 116 | 0.120 |
Why?
|
| Behavior, Animal | 1 | 2017 | 490 | 0.120 |
Why?
|
| Case-Control Studies | 5 | 2011 | 3299 | 0.110 |
Why?
|
| Anxiety Disorders | 2 | 2014 | 689 | 0.110 |
Why?
|
| Executive Function | 2 | 2016 | 109 | 0.110 |
Why?
|
| Creatine | 2 | 2011 | 41 | 0.110 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2015 | 142 | 0.110 |
Why?
|
| Length of Stay | 2 | 2011 | 1310 | 0.100 |
Why?
|
| Terminology as Topic | 2 | 2008 | 223 | 0.100 |
Why?
|
| Volition | 2 | 2006 | 11 | 0.100 |
Why?
|
| Referral and Consultation | 3 | 2024 | 543 | 0.100 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 59 | 0.100 |
Why?
|
| Multiple Sclerosis | 2 | 2007 | 329 | 0.100 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2012 | 22 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2019 | 16353 | 0.100 |
Why?
|
| United States | 6 | 2023 | 10915 | 0.100 |
Why?
|
| Blast Injuries | 1 | 2012 | 58 | 0.100 |
Why?
|
| Inpatients | 2 | 2018 | 499 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2023 | 4817 | 0.090 |
Why?
|
| Anxiety | 1 | 2017 | 957 | 0.090 |
Why?
|
| Forensic Medicine | 1 | 2011 | 12 | 0.090 |
Why?
|
| Neurobiology | 1 | 2011 | 25 | 0.090 |
Why?
|
| Rest | 1 | 2011 | 58 | 0.090 |
Why?
|
| Trauma Severity Indices | 1 | 2011 | 86 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2011 | 3465 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 444 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2023 | 209 | 0.090 |
Why?
|
| Schizophrenic Psychology | 2 | 2002 | 82 | 0.090 |
Why?
|
| Economics | 1 | 2010 | 12 | 0.080 |
Why?
|
| Language Disorders | 1 | 2010 | 23 | 0.080 |
Why?
|
| Supreme Court Decisions | 1 | 2010 | 15 | 0.080 |
Why?
|
| Antidepressive Agents | 2 | 2018 | 293 | 0.080 |
Why?
|
| Adolescent | 6 | 2019 | 19363 | 0.080 |
Why?
|
| Animals | 7 | 2017 | 34232 | 0.080 |
Why?
|
| Phenotype | 1 | 1999 | 4262 | 0.080 |
Why?
|
| Evoked Potentials, Somatosensory | 2 | 1999 | 46 | 0.080 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2009 | 26 | 0.080 |
Why?
|
| Citalopram | 1 | 2009 | 30 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 2107 | 0.080 |
Why?
|
| Capsules | 1 | 2009 | 21 | 0.080 |
Why?
|
| International Classification of Diseases | 1 | 2010 | 90 | 0.080 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2010 | 148 | 0.080 |
Why?
|
| Research | 1 | 2011 | 262 | 0.080 |
Why?
|
| Atrophy | 2 | 2007 | 230 | 0.080 |
Why?
|
| Interpersonal Relations | 1 | 2010 | 230 | 0.080 |
Why?
|
| Time | 1 | 2009 | 92 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2011 | 435 | 0.080 |
Why?
|
| Antibodies | 1 | 2010 | 374 | 0.080 |
Why?
|
| Motor Activity | 2 | 2017 | 520 | 0.080 |
Why?
|
| Consensus | 2 | 2023 | 641 | 0.070 |
Why?
|
| Neurochemistry | 1 | 2008 | 5 | 0.070 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2010 | 149 | 0.070 |
Why?
|
| Medical Records | 1 | 2009 | 192 | 0.070 |
Why?
|
| Dissociative Disorders | 1 | 2008 | 11 | 0.070 |
Why?
|
| Quetiapine Fumarate | 1 | 2007 | 16 | 0.070 |
Why?
|
| Prevalence | 2 | 2021 | 2458 | 0.070 |
Why?
|
| Presenilin-2 | 1 | 2007 | 18 | 0.070 |
Why?
|
| Sex Factors | 2 | 2003 | 1289 | 0.070 |
Why?
|
| Presenilin-1 | 1 | 2007 | 53 | 0.070 |
Why?
|
| Wasting Disease, Chronic | 1 | 2007 | 1 | 0.070 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2007 | 21 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 729 | 0.070 |
Why?
|
| Disease Progression | 2 | 2011 | 2067 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 1324 | 0.070 |
Why?
|
| Accidents, Traffic | 1 | 2007 | 107 | 0.070 |
Why?
|
| Neurosecretory Systems | 1 | 2007 | 23 | 0.070 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2006 | 7 | 0.070 |
Why?
|
| Intelligence Tests | 1 | 2007 | 57 | 0.070 |
Why?
|
| Disease Management | 1 | 2010 | 528 | 0.070 |
Why?
|
| Expressed Emotion | 1 | 2006 | 9 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 2057 | 0.060 |
Why?
|
| Lithium Carbonate | 1 | 2006 | 20 | 0.060 |
Why?
|
| Age Factors | 2 | 2019 | 2823 | 0.060 |
Why?
|
| Incidence | 2 | 2011 | 3147 | 0.060 |
Why?
|
| Biogenic Amines | 1 | 2006 | 20 | 0.060 |
Why?
|
| Illusions | 1 | 2006 | 8 | 0.060 |
Why?
|
| Hydrocortisone | 1 | 2006 | 218 | 0.060 |
Why?
|
| Demography | 1 | 2007 | 239 | 0.060 |
Why?
|
| Cytokines | 1 | 2011 | 1288 | 0.060 |
Why?
|
| Health Surveys | 1 | 2007 | 244 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2006 | 108 | 0.060 |
Why?
|
| Gyrus Cinguli | 2 | 2023 | 116 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2006 | 101 | 0.060 |
Why?
|
| Education | 1 | 2006 | 109 | 0.060 |
Why?
|
| Restraint, Physical | 1 | 2005 | 24 | 0.060 |
Why?
|
| Diazepam | 1 | 2004 | 21 | 0.060 |
Why?
|
| Patient Selection | 1 | 2009 | 699 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2005 | 286 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 320 | 0.060 |
Why?
|
| Psychological Tests | 1 | 2005 | 91 | 0.060 |
Why?
|
| Arm | 1 | 2005 | 81 | 0.060 |
Why?
|
| History, Ancient | 1 | 2004 | 53 | 0.060 |
Why?
|
| Cooperative Behavior | 2 | 2006 | 218 | 0.060 |
Why?
|
| Demyelinating Diseases | 1 | 2004 | 64 | 0.060 |
Why?
|
| Narcotics | 1 | 2004 | 64 | 0.060 |
Why?
|
| Cognitive Aging | 1 | 2024 | 2 | 0.060 |
Why?
|
| Colorado | 3 | 2011 | 21 | 0.060 |
Why?
|
| Inflammation | 1 | 2011 | 1446 | 0.060 |
Why?
|
| Nerve Net | 1 | 2007 | 241 | 0.060 |
Why?
|
| History, 19th Century | 1 | 2004 | 116 | 0.060 |
Why?
|
| Physostigmine | 1 | 2004 | 9 | 0.060 |
Why?
|
| Age of Onset | 1 | 2006 | 595 | 0.060 |
Why?
|
| Time Factors | 2 | 2007 | 6338 | 0.060 |
Why?
|
| Methadone | 1 | 2004 | 126 | 0.060 |
Why?
|
| North America | 1 | 2004 | 241 | 0.050 |
Why?
|
| Corpus Callosum | 1 | 2024 | 97 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2005 | 371 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2004 | 132 | 0.050 |
Why?
|
| Akinetic Mutism | 1 | 2003 | 1 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2005 | 1197 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2023 | 89 | 0.050 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2003 | 5 | 0.050 |
Why?
|
| Electrophysiology | 1 | 2003 | 271 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2004 | 381 | 0.050 |
Why?
|
| Physician's Role | 1 | 2004 | 168 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2006 | 281 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2005 | 390 | 0.050 |
Why?
|
| Auditory Cortex | 1 | 2002 | 29 | 0.050 |
Why?
|
| Geriatric Psychiatry | 1 | 2002 | 11 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2005 | 454 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2005 | 381 | 0.050 |
Why?
|
| Health Services for the Aged | 1 | 2002 | 38 | 0.050 |
Why?
|
| Prefrontal Cortex | 1 | 2023 | 184 | 0.050 |
Why?
|
| Unconsciousness | 1 | 2001 | 17 | 0.050 |
Why?
|
| Acute Disease | 1 | 2004 | 1111 | 0.050 |
Why?
|
| Transdermal Patch | 1 | 2021 | 8 | 0.050 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 334 | 0.040 |
Why?
|
| Psychotherapy | 1 | 2003 | 230 | 0.040 |
Why?
|
| Myelinolysis, Central Pontine | 1 | 2000 | 4 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 4395 | 0.040 |
Why?
|
| Psychomotor Disorders | 1 | 2000 | 28 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2020 | 697 | 0.040 |
Why?
|
| Curriculum | 1 | 2006 | 726 | 0.040 |
Why?
|
| Rehabilitation Research | 1 | 2020 | 1 | 0.040 |
Why?
|
| Corpus Striatum | 1 | 2000 | 92 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2004 | 518 | 0.040 |
Why?
|
| Epilepsies, Partial | 1 | 2000 | 91 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2024 | 495 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 341 | 0.040 |
Why?
|
| Social Stigma | 1 | 2020 | 70 | 0.040 |
Why?
|
| Magnetics | 1 | 1999 | 41 | 0.040 |
Why?
|
| Happiness | 1 | 2019 | 10 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 1999 | 82 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2020 | 92 | 0.040 |
Why?
|
| Mass Screening | 1 | 2005 | 784 | 0.040 |
Why?
|
| Reaction Time | 1 | 2000 | 175 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2000 | 128 | 0.040 |
Why?
|
| Glasgow Outcome Scale | 1 | 2019 | 47 | 0.040 |
Why?
|
| Decision Making | 1 | 2024 | 656 | 0.040 |
Why?
|
| Evoked Potentials | 1 | 2019 | 145 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1242 | 0.040 |
Why?
|
| Temporal Lobe | 1 | 2019 | 112 | 0.040 |
Why?
|
| Reference Values | 1 | 2000 | 718 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 5176 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 436 | 0.040 |
Why?
|
| Gray Matter | 1 | 2018 | 30 | 0.040 |
Why?
|
| Gliosis | 1 | 2017 | 29 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2019 | 284 | 0.040 |
Why?
|
| Syndrome | 1 | 2000 | 1121 | 0.040 |
Why?
|
| Fear | 1 | 2019 | 199 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 1999 | 222 | 0.040 |
Why?
|
| Maze Learning | 1 | 2017 | 128 | 0.030 |
Why?
|
| Aging | 1 | 2024 | 1181 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2004 | 814 | 0.030 |
Why?
|
| Brain Chemistry | 2 | 2009 | 125 | 0.030 |
Why?
|
| Microglia | 1 | 2017 | 102 | 0.030 |
Why?
|
| Biomarkers | 2 | 2011 | 3091 | 0.030 |
Why?
|
| Academic Medical Centers | 2 | 2010 | 308 | 0.030 |
Why?
|
| Models, Animal | 1 | 2017 | 464 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2015 | 113 | 0.030 |
Why?
|
| Astrocytes | 1 | 2017 | 249 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 683 | 0.030 |
Why?
|
| Software | 1 | 1999 | 684 | 0.030 |
Why?
|
| Caregivers | 1 | 2020 | 574 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 1438 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 1420 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 306 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2010 | 1396 | 0.030 |
Why?
|
| Child | 2 | 2019 | 24421 | 0.030 |
Why?
|
| Risk Factors | 2 | 2004 | 10315 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 2013 | 140 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2004 | 3073 | 0.020 |
Why?
|
| Creatinine | 1 | 2013 | 391 | 0.020 |
Why?
|
| Visual Perception | 1 | 2011 | 124 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 589 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 3425 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2011 | 398 | 0.020 |
Why?
|
| Neurofibrillary Tangles | 1 | 2007 | 26 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2007 | 40 | 0.020 |
Why?
|
| Pituitary Hormones, Anterior | 1 | 2007 | 3 | 0.020 |
Why?
|
| Disease Reservoirs | 1 | 2007 | 35 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2010 | 259 | 0.020 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2007 | 21 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 140 | 0.020 |
Why?
|
| Thyrotropin | 1 | 2007 | 56 | 0.020 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2007 | 14 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2007 | 76 | 0.020 |
Why?
|
| Psychomotor Agitation | 1 | 2007 | 56 | 0.020 |
Why?
|
| Prolactin | 1 | 2007 | 114 | 0.020 |
Why?
|
| Introns | 1 | 2007 | 300 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2007 | 359 | 0.020 |
Why?
|
| Antiemetics | 1 | 2006 | 22 | 0.020 |
Why?
|
| Stereotyping | 1 | 2006 | 19 | 0.020 |
Why?
|
| Point Mutation | 1 | 2007 | 348 | 0.020 |
Why?
|
| Benzamides | 1 | 2006 | 109 | 0.020 |
Why?
|
| Saliva | 1 | 2006 | 114 | 0.020 |
Why?
|
| Axons | 1 | 2009 | 369 | 0.020 |
Why?
|
| Vomiting | 1 | 2006 | 105 | 0.020 |
Why?
|
| Mental Processes | 1 | 2005 | 40 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 2005 | 52 | 0.020 |
Why?
|
| Skull | 1 | 2006 | 141 | 0.010 |
Why?
|
| Carbamazepine | 1 | 2005 | 48 | 0.010 |
Why?
|
| MEDLINE | 1 | 2005 | 20 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 2005 | 107 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 816 | 0.010 |
Why?
|
| Language | 1 | 2005 | 197 | 0.010 |
Why?
|
| Pain | 1 | 2007 | 451 | 0.010 |
Why?
|
| Central Nervous System | 1 | 2005 | 255 | 0.010 |
Why?
|
| Radiography | 1 | 2005 | 823 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1697 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2005 | 265 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 2004 | 359 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 17631 | 0.010 |
Why?
|
| Median Nerve | 1 | 1999 | 16 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 1999 | 326 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1999 | 320 | 0.010 |
Why?
|